A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators

Journal of Medicinal Chemistry

Volumn 49, Issue 26, 2006, Pages 7646-7660

  Labrie, Philippe ^a,b   Maddaford, Shawn P ^c   Fortin, Sebastien ^a   Rakhit, Suman ^c   Kotra, Lakshmi P ^d,e   Gaudreault, René C ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c NeurAxon Inc MaRS Centre   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBENZAMIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; HYDROGEN BOND; HYDROPHOBICITY; IC 50; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY;

ANTHRANILIC ACIDS; DAUNORUBICIN; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845948232     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060239b     Document Type: Article

References (59)

1. Young, R. C. Drug resistance: the clinical problem. In Drug Resistance in Cancer Therapy; Ozols, R. F., Ed.; Kluwer Academic Publishers: Boston, MA, 1989; pp 1-12.
2. Robert, J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur. J. Clin. Invest. 1999, 29, 536-545.
3. Nussler, V.; Pelka-Fleischer, R.; Zwierzina, H.; Nerl, C.; Beckert, B.; Gullis, E.; Gieseler, F.; Bock, S.; Bartl, R.; Petrides, P. E.; Wilmanns, W. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes-first experience with their reversal. Ann. Hematol. 1994, 69 (Suppl. 1), S25-S29.
4. Juliano, R.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem. Biophys. Acta 1976, 455, 152-162.
5. Endicott, J.; Ling, V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu. Rev. Biochem. 1989, 58, 137-171.
6. Gottesman, M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
7. Abraham, E. H.; Prat, A. G.; Gerweck, L.; Seneveratne, T.; Arceci, R. J.; Kramer, R.; Guidotti, G.; Cantiello, H. F. The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 312-316.
8. Roepe, P. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Biochemistry 1992, 31, 12555-12564.
9. Zhu, T. A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol. Carcinog. 1999, 25, 1-13.
10. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981, 41, 1967-1972.
11. Slater, L. M.; Sweet, P.; Stupecky, M.; Gupta, S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 1986, 77, 1405-1408.
12. Arceci, R. J.; Stieglitz, K.; Bierer, B. E. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992, 80, 1528-1536.
13. Tsuruo, T.; Iida, H.; Kitatani, Y.; Yokota, K.; Tsukagoshi, S.; Sakurai, Y. Effects of quinidine and related compounds on cytotoxic and cellular accumulation of vincristine and adriamycin in drug resistant tumor cells. Cancer Res. 1984, 44, 4303-4307.
14. Tsuruo, T.; Iida, H.; Nojiri, M.; Tsukagoshi, S.; Sakurai, Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983, 43, 2905-2910.
15. Beck, W. T.; Danks, M. K. Characteristics of multidrug resistance in human tumor cells. In Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells; Roninson, I. B., Ed.; Plenum Press: New York, 1991; pp 3-46.
16. Beck, W. Modulators of P-glycoprotein associated multidrug resistance. In Molecular and Clinical Advances in Anticancer Drug Resistance; Ozols, R. F., Ed.; Kluwer Academic Publishers: Philadelphia, PA, 1991; pp 151-170.
17. Benson, A. B.; Trump, D. L.; Koeller, J. M.; Egorin, M. I.; Olman, E. A.; Witte, R.; Tormey, D. C. Phase I study of vinblastine and verapamil given by concurrent iv infusion. J. Clin. Oncol. 1985, 3, 311-315.
18. Miller, T. P.; Grogan, T. M.; Dalton, W. S.; Spier, C. M.; Scheper, R. J.; Salmon, S. E. P-glycoprotein expression in malignant lymphomas and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 1991, 9, 17-24.
19. Trump, D. L.; Smith, D. C.; Ellis, P. G.; Rogers, M. P.; Schold, S. C.; Winer, E. P.; Jordan, V. C.; Fine, R. L. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J. Natt. Cancer Inst. 1992, 84, 1811-1816.
20. Christen, R. D.; McClay, E. F.; Plaxe, S. C.; Yen, S. S.; Kim, S.; Kirmani, S.; Wilgus, L. L.; Heath, D. D.; Shalinsky, D. R.; Freddo, J. L. Phase 1/pharmacokinetic study of high-dose progesterone and doxorubicin. J. Clin. Oncol. 1993, 11, 2417-242.
21. Bartlett, N. L.; Lum, B. L.; Fisher, G. A.; Brophy, N. A.; Ehsan, M. N.; Halsey, J.; Sikic, B. I. Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J. Clin. Oncol. 1994, 12, 835-842.
22. Boekhorst, P. A.; Van, K. J.; Schoester, M.; Sonneveld, P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing mdr1 phenotype. Cancer Chemother. Pharmacol. 1992, 30, 238-342.
23. Roe, M.; Folkes, A.; Ashworth, P.; Brumwell, J.; Chima, L.; Hunjan, S.; Pretswell, I.; Dangerfield, W.; Ryder, H.; Charlton, P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Lett. 1999, 9, 595-600.
24. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 1999, 128, 403-411.
25. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multiple resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53, 4595-4602.
26. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of P-glycoprotein- mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator LY335979. Cancer Res. 1996, 56, 4171-4179.
27. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001, 61, 749-758.
28. Deleted in proof.
29. Deleted in proof.
30. Pearce, H. L.; Safa, A. R.; Bach, N. J.; Winter, M. A.; Cirtain, M. C.; Beck, W. T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 5128-5132.
31. Pearce, H. L.; Winter, M. A.; Beck, W. T. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv. Enzyme Regul. 1990, 30, 357-373.
32. Ramu, A.; Ramu, N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother. Pharmacol. 1992, 30, 165-173.
33. Chiba, P.; Ecker, G.; Schmid, D.; Drach, J.; Tell, B.; Goldenberg, S.; Gekeler, V. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol. 1996, 49, 1122-1130.
34. Pajeva, I. K.; Wiese, M. QSAR and molecular modeling of catamphiphilic drugs able to modulate multidrug resistance in tumors. Quant. Struct.-Act. Relat. 1977, 16, 1-10.
35. Salem, M.; Richter, E.; Hitzler, M.; Chiba, P.; Ecker, G. Studies on propafenone type modulators of multidrug resistance VIII: synthesis and pharmacological activity of indanone analogues. Sci. Pharm. 1996, 66, 147-158.
36. Pajeva, I. K.; Wiese, M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J. Med. Chem. 1998a, 41, 1815-1826.
37. Pajeva, I. K.; Wiese, M. A comparitive molecular field analysis of propafenone-type modulators of cancer multidrug resistance. Quant. Struct.-Act. Relat. 1998b, 17, 301-312.
38. Ecker, G.; Huber, M.; Schmid, D.; Chiba, P. The importance of a nitrogen atom in modulators of multidrug resistance. Mol. Pharmacol. 1999, 56, 791-796.
39. Schmid, D.; Ecker, G.; Kopp, S.; Hitzler, M.; Chiba, P. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem. Pharmacol. 1999, 58, 1447-1456.
40. Seelig, A. How does P-glycoprotein recognize its substrates? Int. J. Clin. Pharmacol. Ther. 1999, 36, 50-54.
41. Ryder, H.; Ashworth, P. A.; Roe, M. J.; Brumwell, J. E.; Hunjan, S.; Folkes, A. J.; Sanderson, J. T.; Williams, S.; Maximen, L. M. Anthranilic acid derivatives as multi drug resistance modulators. WO98/17648, April 30, 1998.
42. Klebe, G. Comparative molecular similarity indices analysis: CoMSIA. In 3D QSAR in Drug Design; Kubinyi, H., Folkers, G., Martin, Y. C., Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1998; Vol. 3, pp 87-104.
43. Globisch, C.; Pajeva, I. K.; Wiese, M. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg. Med. Chem. 2006, 5, 1588-1598.
44. Ford, J. M.; Prozialeck, W. C.; Heit, W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 1989, 35, 105-115.
45. Ford, J. M.; Briggeman, E. P.; Pastan, I.; Gottesman, M.; Hait, W. N. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990, 50, 1748-1756.
46. Ramu, A. In Resistance to Antineoplastic Drugs; Kessel, D., Ed.; CRC: Boca Raton, FL, 1989; pp 63-80.
47. Bush, A.; Martin-Pastor, M. Structure and conformation of complex carbohydrate of glycoproteins, glycolipids, and bacterial polysaccharides C. Annu. Rev. Biophys. Biomol. Struct. 1999, 28, 269-293.
48. Jain, A. N.; Koile, K.; Chapman, D. Compass: predicting biological activities from molecular surface properties, performance comparisons on a steroid benchmark. J. Med. Chem. 1994, 37, 2315-2327.
49. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput.-Aided Mol. Des. 1993, 7, 83-102.
50. Pearlman, R. S. 3D QSAR in Drug Design. Theory, Methods, and Applications; ESCOM Science: Leiden, The Netherlands, 1993.
51. Pajeva, I. K.; Globisch, C.; Wiese, M. Structure-function relationships of multidrug resistance P-glycoprotein. J. Med. Chem. 2004, 47, 2523-2533.
52. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, R. K. Atomic physichochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
53. Klebe, G. The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands. J. Mol. Biol. 1994, 237, 212-235.
54. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E.; Frank, I. E. Cross-validation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
55. Agrafiotis, D. K.; Cedeno, W.; Lobanov, V. S. On the use of neural network ensembles in QSAR and QSPR. J. Chem. Inf. Comput. Sci. 2002, 42, 903-911.
56. Wehrens, R.; van der Linden, W. E. Bootstrapping principal component regression models. J. Chemom. 1997, 11, 157-171.
57. Kubinyi, H.; Hamprecht, F. A.; Mietzner, T. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. J. Med. Chem. 1998, 41, 2553-2564.
58. 2. J. Mol. Graphics Modell. 2002, 20, 269-276.
59. Bang, S. J.; Cho, S. J. Comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) study of mutagen X. Bull. Korean Chem. Soc. 2004, 25, 1525-1530.